Generation of B-cell-based cellular vaccine for cancer in murine models.

A B-cell-based cellular vaccine (B), produced from 4-1BBL B cells, can select tumor-specific B cells that, upon ex vivo culture, can generate tumor-specific antibodies and activate T cells. Here, we present a protocol to generate a B-cell-based vaccine in a CT2A orthotopic glioma murine model. We describe steps for B production involving glioma cell implantation, tissue harvesting, 4-1BBL B cell isolation, and activation. We also describe assessing B phenotype in vitro and in vivo functional status. For complete details on the use and execution of this protocol, please refer to Lee-Chang et al. (2021)..